{"id":"NCT03313180","sponsor":"Boehringer Ingelheim","briefTitle":"A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis","officialTitle":"An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With 'Systemic Sclerosis Associated Interstitial Lung Disease' (SSc-ILD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-27","primaryCompletion":"2023-01-25","completion":"2023-01-25","firstPosted":"2017-10-18","resultsPosted":"2024-02-20","lastUpdate":"2024-02-20"},"enrollment":444,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Lung Diseases, Interstitial"],"interventions":[{"type":"DRUG","name":"Nintedanib","otherNames":["OVEF"]}],"arms":[{"label":"Nintedanib","type":"EXPERIMENTAL"}],"summary":"The main objective is to assess long term safety of treatment with oral nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD).","primaryOutcome":{"measure":"Number of Patients With Any Adverse Event (AE) Over the Course of the Trial","timeFrame":"First trial medication intake up to last trial drug intake, plus 7 days residual effect period, up to approximate 60 months.","effectByArm":[{"arm":"Nintedanib","deltaMin":441,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":15},"locations":{"siteCount":159,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","Denmark","Finland","France","Germany","Greece","India","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Norway","Poland","Portugal","Spain","Sweden","Switzerland","Thailand","United Kingdom"]},"refs":{"pmids":["37294870"],"seeAlso":["http://www.mystudywindow.com"]},"adverseEventsSummary":{"seriousAny":{"events":198,"n":444},"commonTop":["Diarrhoea","Nausea","Skin ulcer","Vomiting","Cough"]}}